The breast cancer promoting eects of estrogen and the chemopreventive eects of tamoxifen are thought to be mediated by the estrogen receptor, a ligand-dependent transcription factor. Therefore, comprehensive analysis of gene expression pro®les following estrogen or tamoxifen treatment may help us better understand the role estrogen plays in tumorigenesis. We utilized SAGE (Serial Analysis of Gene Expression) technology to identify genes regulated by estrogen and tamoxifen in the ZR75-1 estrogen dependent breast cancer cell line. In this manner we have identi®ed several genes that were regulated by estrogen or tamoxifen. Here we report the identi®cation and initial characterization of EIT-6 (Estrogen Induced Tag-6), a novel nuclear protein and a new member of the evolutionarily conserved SM-20 family of growth regulatory immediate-early genes. EIT-6 appears to be a direct transcriptional target of the estrogen receptor and constitutive expression of EIT-6 promotes colony growth in human breast cancer cells. These data indicate that EIT-6 may play a role in estrogen induced cell growth.
The breast cancer promoting eects of estrogen and the chemopreventive eects of tamoxifen are thought to be mediated by the estrogen receptor, a ligand-dependent transcription factor. Therefore, comprehensive analysis of gene expression pro®les following estrogen or tamoxifen treatment may help us better understand the role estrogen plays in tumorigenesis. We utilized SAGE (Serial Analysis of Gene Expression) technology to identify genes regulated by estrogen and tamoxifen in the ZR75-1 estrogen dependent breast cancer cell line. In this manner we have identi®ed several genes that were regulated by estrogen or tamoxifen. Here we report the identi®cation and initial characterization of EIT-6 (Estrogen Induced Tag-6), a novel nuclear protein and a new member of the evolutionarily conserved SM-20 family of growth regulatory immediate-early genes. EIT-6 appears to be a direct transcriptional target of the estrogen receptor and constitutive expression of EIT-6 promotes colony growth in human breast cancer cells. These data indicate that EIT-6 may play a role in estrogen induced cell growth. Oncogene (2002) 21, 836 ± 843. DOI: 10.1038/sj/onc/ 1205113 Keywords: estrogen; tamoxifen; SAGE (Serial Analysis of Gene Expression); breast cancer Breast cancer is a leading cause of cancer death in women of the Western world (Greenlee et al., 2000) . Despite advances in early detection and treatment, breast cancer mortality rates have not decreased signi®cantly over the past few decades. Thus, there is a continued and increasing need for the identi®cation of risk factors of breast cancer and molecular targets of chemoprevention in order to decrease the incidence of this disease. Estrogen plays a key role in the development of the normal mammary gland and in the initiation and progression of breast carcinomas (Nandi et al., 1995) . Clinical trials using anti-estrogens (tamoxifen) proved the importance of estrogens in breast tumor development, and identi®ed tamoxifen as a breast cancer preventive agent (Fisher et al., 1998 (Fisher et al., , 1999 . However, there is little known about the mechanisms that account for the tumorigenic eects of estrogen and the cancer preventive eects of tamoxifen.
The action of estrogen is mediated by its receptors (estrogen receptors-ERa and b), members of the nuclear hormone receptor family and ligand-dependent transcription factors (Katzenellenbogen, 1996; Mangelsdorf et al., 1995) . Estrogen binding stimulates the trans-activating function of ER through its ability to facilitate the recruitment of various receptor binding co-activator proteins (Freedman, 1999) . These receptor-co-activator complexes then aect transcription initiation at promoters regulated by estrogen. Antiestrogens not only preclude co-activator binding, but can facilitate the recruitment of co-repressors and lead to active repression of the basal expression of certain genes. Many of the co-activators and co-repressors are cell type and dierentiation stage speci®c, therefore their interaction with ER may explain the diverse, sometimes opposing eects of estrogen and tamoxifen in dierent cell types. Several studies have been performed to identify genes whose expression is modulated by estrogen or tamoxifen treatment (Charpentier et al., 2000; Inadera et al., 2000; Manning et al., 1988 Manning et al., , 1990 Manning et al., , 1995 . Several growth factors, growth factor receptors, extracellular proteins, immediate-early genes and cell cycle regulators that may have eects on mammary carcinogenesis have been identi®ed as potential targets of the estrogen-signaling pathway (de Cupis and Favoni, 1997; Katzenellenbogen et al., 1997) . However, none of these induced genes can fully explain the mitogenic eects of estrogen or the chemopreventive eects of tamoxifen. In addition, there is an increasing need to identify new estrogen and tamoxifen targets that could be used as biomarkers to monitor the ecacy of cancer treatment and prevention.
In order to determine the global cellular response of breast cancer cells to estrogen and tamoxifen, we have generated SAGE (Serial Analysis of Gene Expression) libraries from an estrogen dependent human breast cancer cell line (ZR75-1) prior to and following estrogen or tamoxifen treatment. SAGE enabled us to determine the absolute abundance of thousands of dierent mRNAs simultaneously in a comprehensive and unbiased way and to detect even slight dierences in expression levels between samples (Velculescu et al., 1995) . ZR75-1 cells cultured in the absence of endogenous hormones for 7 days were switched to fresh medium in the absence or presence of 10 nM estradiol or 10 mM 4-hydroxy-tamoxifen. Cells were collected after 16 h and response to the hormonal treatment was con®rmed by FACS analysis of cell cycle progression and by Northern blot analysis using known estrogen target genes. Estrogen deprived ZR75-1 arrested in G1 and G2 phases of the cell cycle, while addition of estrogen, and to a lesser degree tamoxifen, stimulated rapid S phase entry (data not shown). SAGE libraries from untreated, estrogen or tamoxifen treated cells were generated using a modi®ed micro-SAGE protocol (Porter et al., 2001) . From the three SAGE libraries 140 638 tags were obtained, approximately 45 000 from each library (SAGE data will be deposited at http://www.ncbi.nlm.nih.gov/ SAGE/). Pair-wise comparison and statistical analysis of these libraries led to the identi®cation of several estrogen and/or tamoxifen induced transcripts. There were 61 tags (33 up-regulated and 22 down-regulated) that showed at least twofold dierence (P50.001) between the estrogen treated and control libraries, while 15 tags (nine up-regulated and six downregulated) showed at least twofold dierence (P50.001) between the tamoxifen treated and control libraries. In addition, we found 22 tags that were signi®cantly elevated in the estrogen treated cells when compared to the tamoxifen treated ones, while 24 tags were signi®cantly elevated in the tamoxifen treated library compared to the estrogen treated one. Linking the UniGene database to our SAGE data identi®ed the cDNAs corresponding to the SAGE tags in most of the cases (Table 1) . Genes were named according to their abundance in the three SAGE libraries: EIT (Estrogen Induced Tag)-induced by estrogen, TIT (Tamoxifen Induced Tag) -induced by tamoxifen, DET (Dierently Expressed Tag)-dierently expressed following estrogen or tamoxifen treatment.
Since SAGE tag numbers re¯ect the absolute abundance of the mRNAs, data obtained from dierent experiments performed in dierent laboratories are directly comparable (Velculescu et al., 1995) . Therefore, our data and SAGE libraries generated from untreated or estrogen treated MCF-7 cells by others (Charpentier et al., 2000) were analysed using a clustering algorithm to delineate similarities and dierences between the eects of estrogen in two dierent breast cancer cell lines (Figure 1a ). Correlating with previous studies the two breast cancer cell lines had distinct genes expression patterns and demonstrated a discrete transcriptional response to estrogen treatment (Perou et al., 2000) . Among the known estrogen target genes, cathepsin D was induced by estrogen in both cells lines, whereas pS2 and cyclin D1 were induced only in MCF-7 cells (Figure 1a ). All three SAGE libraries derived from the same cell line were more similar to each other, even after estrogen treatment, than to the other cell line. Interestingly, untreated and estrogen treated MCF-7 cells were highly similar to each other, while tamoxifen treated and untreated ZR75-1 cells were somewhat more similar to each other and distinct from estrogen treated cells. These ®ndings indicate that estrogen exerts a diering eect depending on the cellular context, and overall there are relatively few genes signi®cantly aected by estrogen or tamoxifen treatment in these breast cancer cell lines.
To validate the result of the SAGE experiment we have generated probes corresponding to some of the cDNA clones and con®rmed their induction by Northern blot analysis (Figure 1b) . From the 20 estrogen or tamoxifen induced genes (Table 1) only one (EIT-10=cathepsin D) had been implicated as a target of ER-transcriptional activation, and three had not previously been described at all. In most of the cases the sequences of the genes provided important clues as to their potential functions (Table 1 ). In particular, several of these genes are predicted to be involved in the regulation of cell proliferation and/or survival. EIT-2 is a protein translocase involved in importing nuclear encoded proteins to the mitochondria (Bauer et al., 1999) ; EIT-4 is a human homologue of the yeast Dim1p gene essential for mitosis (Berry and Gould, 1997) , EIT-6 is an EST homologous to a rat immediate-early gene SM-20 (Wax et al., 1994) ; TIT-5 is an anti-apoptotic member of the bcl-2 family (Xu and Reed, 1998) ; and DET-15 and DET-16 are both putative transcription factors with anti-proliferative activity (Ismail et al., 1999; Nakashiro et al., 1998; Shibanuma et al., 1992) . Although several ESTs have no homology to known genes, their expression pattern in other SAGE libraries suggests that they also might play a role in cell proliferation and/or estrogen mediated responses (Lal et al., 1999) . For example, the TIT-3 and TIT-1 genes appear to be elevated in ER+DCIS (Ductal Carcinoma In Situ) compared to corresponding normal mammary epithelium and expressed at much lower levels in other cell types (Porter et al., 2001) . Interestingly, one of the tamoxifen induced genes, SULT1A phenol sulfotransferase, is an enzyme involved in the metabolism of environmental carcinogenes and steroid hormones including estrogen and tamoxifen (Weinshilboum et al., 1997) . Recently we and others reported that polymorphism in SULT1A1 in¯uences the age-of onset and the risk of breast cancer, respectively (Seth et al., 2000) ; Zheng et al., 2001) .
Although our SAGE analysis led to the isolation of several novel estrogen and/or tamoxifen regulated genes, it provided no information on which of these genes might be key mediators of the cellular response initiated by estrogen and/or tamoxifen. However, one of the estrogen induced genes, EIT-6, appeared to be particularly interesting due to its relatively high abundance in SAGE libraries prepared from hormone responsive tissues (normal and cancerous mammary, Figure 1 Expression analysis of novel estrogen and tamoxifen induced genes. (a) Variation in expression of 2818 genes in six SAGE libraries and dendogram representing similarities in expression pattern among samples. Only parts of certain clusters are included in the ®gure. These clusters are genes more abundant in ZR75-1 (A) or MCF-7 (B) cells, genes with fairly equal levels in both cell lines and libraries (C), genes induced by estrogen either in ZR75-1 or MCF-7 cells (D) and genes more abundant in tamoxifen and estrogen treated (E) or tamoxifen treated and untreated ZR75-1 (F) cells. Each row represents a gene/SAGE tag, while each column corresponds to a SAGE library. MU, ME3, and ME10 denote MCF-7 cells untreated, estrogen treated for 3, or 10 h, respectively. Similarly ZU, ZE, and ZT stand for untreated, estrogen, or tamoxifen treated ZR75-1 cells. The absolute abundance of the SAGE tag in the library (SAGE tag number) correlates with red color intensity (black=not present ± intense red=highly abundant). Genes highlighted in red correspond to known estrogen targets or genes statistically signi®cantly aected by hormonal treatment. (b) Correlation of Northern blot (left panel) and SAGE (right panel; results for the indicated genes. Numbers represent SAGE tag numbers. RNA and SAGE libraries were prepared from untreated (C), estrogen (E) and tamoxifen (T) treated cells. CATH D and PR denotes cathepsin D and progesterone receptor, respectively. (c) In vivo expression of EIT-6 in normal breast tissue. Histological sections of normal human breast tissue were stained with hematoxylin-eosin (H&E). Adjacent slides were hybridized with P 33 labeled EIT-6 anti-sense or sense probes and visualized using dark-®eld microscopy. Intense hybridization signal is detected in mammary epithelial cells using the antisense, but not the sense probe. (d) Analysis of EIT-6 mRNA levels in various ovarian and prostate epithelium) (Lal et al., 1999; Lash et al., 2000) , and we therefore characterized it in further detail. A full-length (2071 bp) human EIT-6 cDNA was obtained by analysing and sequencing ESTs clones. The human EIT-6 cDNA contains an open reading frame (ORF) of 1221 bp encoding a predicted protein of 407 amino acids (*43 000 Daltons), which was con®rmed by in vitro transcription/translation experiments (data not shown). By FISH analysis we localized EIT-6 to chromosome 19q13.1, a region not previously implicated in breast cancer (data not shown). We also analysed the in vivo abundance of the EIT-6 mRNA and determined its expression at the cellular level by mRNA in situ hybridization of normal human breast tissue (Figure 1c ). EIT-6 hybridization signal showed fairly even intensity throughout the mammary epithelium, while no signi®cant signal was detected in stromal cells.
To determine how generally EIT-6 is regulated by estrogen, we performed Northern blot analysis of various ER+breast and endometrial cancer cell lines (Figure 1d ). In addition to being induced in ZR75-1 cells (*5-fold induction), the cell line used for the generation of the SAGE libraries, EIT-6 is induced in BT-474 cells (*10-fold induction), but not in other estrogen responsive cell lines analysed. This ®nding is not unexpected, since many estrogen targets are induced in a cell type speci®c manner.
To determine if the induction of EIT-6 by estrogen is ER mediated, we analysed the eect of estrogen antagonists (4-hydroxy-tamoxifen and ICI 182 780) on EIT-6 mRNA levels (Figure 1e) . Consistent with our SAGE data, EIT-6 was induced only by estrogen, and this induction was completely or partially abolished by the addition of ICI 182 780 or tamoxifen, respectively. Thus, the increase in EIT-6 mRNA levels following estrogen treatment is both estrogen and ER dependent. There are multiple ways estrogen may be regulating the expression levels of EIT-6: (1) direct transcriptional regulation; (2) in¯uencing mRNA stability; or (3) indirectly through other transcription factors/signaling pathways. Northern blot analysis of EIT-6 mRNA levels at dierent time points following estrogen treatment indicated that EIT-6 is induced by estrogen at about the same time as cathepsin D, a known direct estrogen target, (Figure 2a ). This result suggests that EIT-6, similar to cathepsin D, may also be a direct transcriptional target of ER. Addition of transcription inhibitors completely abolished EIT-6 induction by estrogen indicating that increased EIT-6 mRNA levels are likely due to increased transcription (data not shown). To further investigate if EIT-6 is a breast (ZR75-1, BT-474, T47D, MCF-7) and endometrial (RL95-2, HEC-1A) cancer cell lines following estrogen (E) or tamoxifen (T) treatment. Estrogen receptor (ER) status of the cell lines are indicated by`+' and`7' signs. (e) EIT-6 expression in cells treated with no drug (C), estrogen (E), tamoxifen (T), ICI 128 780 (ICI) or with combinations of estrogen and tamoxifen (E+T) and estrogen and ICI (E+ICI). Breast cancer cell lines were obtained from American Type Culture Collection and maintained according to the supplier. To assay estrogen responsiveness cells were cultured in phenol red free medium (Life Technologies) supplemented with 5% charcoal treated fetal bovine serum (Hyclone) after which cells were switched to fresh medium or fresh medium containing 10 nM estradiol or 10 mM 4-hydroxy-tamoxifen. SAGE libraries were generated and analysed as previously described (Porter et al., 2001) . Hierarchical clustering was applied to data using the Cluster program developed by Eisen et al. (1998) . Data was logtransformed and ®ltered for at least one observations abs Val 5 and Maxval-Minval45. Using these settings 2818 genes (out of 16 808 total) were included in the analysis. Results were displayed with the TreeView program (Eisen et al., 1998) . mRNA in situ hybridizations using a P 33 labeled sense or anti-sense EIT-6 ribo-probes were performed as described (Rosen et al., 1999) . The eect of estrogen antagonists was determined by pre-incubating the cells with 1 mM ICI 128 780 or 10 mM 4-hydroxy-tamoxifen for 6 h followed by estrogen treatment for an additional 24 h. RNA isolation, RT ± PCR and Northern blot analyses were performed as described (Polyak et al., 1997) (Figure 2b ). Cycloheximide and estrogen both increased EIT-6 mRNA levels to a certain degree, but estrogen treatment in the presence of cycloheximide led to a much stronger induction. Based on these results, the induction of EIT-6 following estrogen treatment does not appear to require new protein synthesis. Therefore, EIT-6 is likely to be a direct transcriptional target of ER, but the possibility that other proteins are also involved in the transcriptional activation of EIT-6 cannot be excluded.
To further characterize the mechanism by which ER induces EIT-6, ®rst we determined if a *5.5 kb fragment of the proximal EIT-6 promoter confers estrogen responsiveness to a luciferase reporter gene.
Measurement of luciferase activity in 911 cells following transient transfection of this construct with co-transfected ERa demonstrated a modest, but reproducible induction following estrogen treatment (Figure 2c) . Random 2 ± 3 kb fragments derived from the EIT-6 genomic region placed up-stream of a luciferase gene conferred no response to estrogen treatment (data not shown). Next, we analysed the sequence of this promoter region and identi®ed several potential estrogen responsive elements (ERE) closely resembling the consensus ERE sequence (Figure 2d ). To determine whether these putative EREs can confer estrogen responsiveness, we generated various constructs with concatemers of each of these elements or their combination placed up-stream of a luciferase gene (Figure 2d ). Measurement of luciferase activity following transient transfection of these constructs with co- Fold induction by estrogen is indicated on y-axis. Numbers are average of three independent experiments performed in quadruplicate, luciferase activity was normalized for transfection eciency by using the ratio of luciferase to b-galactosidase activity. A construct containing two copies from the vitillogenin. A promoter was used as positive control (VIT) (McMahon et al., 1999) . Estrogen treatment, RNA isolation and Northern blot analysis was performed as described above. The eect of cycloheximide (CHX) was assayed by treating the cells with 10 mg/ml CHX for 16 h in the presence or absence of estrogen. EIT-6 promoter luciferase reporter constructs were generated by subcloning a *5.5 kb BAC (bacterial arti®cial chromosome) derived fragment of the EIT-6 promoter or concatemers of PCR-derived fragments of the human EIT-6 promoter containing the putative EREs into pBR-pl-luc or pBR-pl-TATA-luc, respectively (Polyak et al., 1997) . Cells were transfected using FuGene6 (Roche), treated with estrogen the day after transfection and the following day luciferase and b-galactosidase activities were determined using a luciferase assay system (Promega) and the Aurora GAL-XE reporter gene assay (ICN), respectively transfection of ERa in HepG2 cells revealed that most of them demonstrated some, although relatively weak, estrogen responsiveness (Figure 2e ). The most signi®-cant (4 ± 5 fold) induction was observed using the E4 construct containing three copies of the E4 ERE. This ERE is closest to the transcription start site and contains a nearly perfect ERE with only two mismatches compared to the consensus sequence. In the same experiments two copies of the consensus ERE derived from the vitillogenin promoter (VIT) led to a 10 ± 11-fold induction in luciferase activity following estrogen treatment (Figure 2e ). Therefore, a 4 ± 5-fold induction observed with the E4 ERE is signi®cant and indicates that this fragment could be a functional ERE. Although these experiments do not prove that any of these putative EREs are necessary for the induction of EIT-6 by estrogen, they do show that these elements can confer estrogen responsiveness. Therefore, direct binding of ER to these putative EREs may be responsible for the transcriptional induction of EIT-6, but other mechanisms cannot be excluded.
EIT-6 is a novel human gene and although it is homologous to the SM-20 rat immediate-early gene induced by growth agonists (Wax et al., 1994) , it is not ) are plotted on the y axis. Results are the average of three independent experiments. For intracellular localization studies EIT-6-GFP fusion fragment was PCR ampli®ed as described (Flatt et al., 2000) and subcloned into pShuttle-CMV construct (He et al., 1998) . Cells were transfected with pEGFP-N, pEGFP-mito (Clonetech) or pShuttle-EIT-6-GFP plasmids and analysed by¯uorescence microscopy. To assay colony growth expression construct was generated by subcloning a PCR derived EIT-6 cDNA with a C-terminal double hemagglutinin (HA2) tag into pCEP4 (Invitrogen). T47D cells were transfected with FuGene6 (Roche) and selected in hygromycin containing medium for 2 weeks after which colonies were visualized by crystal violet staining. The number of colonies/cm 2 was determined based on spot-densitometry assisted counting using a MultiImage Lightbox (Alfa Innotech). Two independent areas/¯ask and twō asks/experiments were analysed. In some experiments the cells were grown in regular 10% fetal bovine serum (FBS) containing RPMI medium, while in other experiments cells were cultured in phenol red free RPMI medium (Life Technologies) supplemented with 5% charcoal treated FBS (Hyclone) in the presence or absence or 10 nM estradiol the human orthologue of this rat gene (Figure 3a) . However, similar to SM-20, EIT-6 is also induced by various growth agonists (EGF, isoproterenol, and PMA) in ZR75-1 cells (data not shown). The rat SM-20 cDNA was also identi®ed as a gene induced by wild-type p53 and as a gene induced in sympathetic neurons during NGF (Nerve Growth Factor) withdrawal initiated apoptosis (Lipscomb et al., 1999; Madden et al., 1996) . Subsequent experiments in muscle cells determined that SM-20 may play a role in the regulation of myoblast proliferation and dierentiation (Moschella et al., 1999) . Interestingly, a recent study isolated another SM-20/ EIT-6 homologue as a gene signi®cantly overexpressed in over 50% of endometrial carcinomas, the development of which is thought to depend on estrogenic hormones (Foca et al., 2000) . Based on these results we can conclude that EIT-6 is a member of a multi gene family of growth regulatory genes that includes SM-20, EIT-6, and additional SM-20 homologues. EIT-6 appears to encode a protein with evolutionarily conserved function: there is a C. elegans EIT-6 homologue ( Figure 3a ,b) that was identi®ed as an egg laying defective mutant (egl-9) (Trent et al., 1983) , and several additional SM-20/EIT-6 homologues were identi®ed from various other species including several types of bacteria (Figure 3b) . Surprisingly immunohistochemical analysis of the rat SM-20 gene demonstrated cytoplasmic staining, while the human SM-20 orthologue, another related human gene (SCAND2), and EIT-6 all contain putative nuclear localization signals (Dupuy et al., 2000; Wax et al., 1994) . However, most of the homology between EIT-6 and SM-20 resides in the C-terminal region, while the N-terminal domain (containing the nuclear localization sequence) are divergent. Therefore, to determine the sub-cellular localization of EIT-6, we generated a construct expressing an EIT-6-GFP (Green Fluorescence Protein) fusion protein. Fluorescence microscopic analysis of cells transiently transfected with control GFP and mitochondrial-GFP (mito-GFP) encoding constructs revealed mostly cytoplasmic and mitochondrial localization, respectively (Figure 3c ). In contrast, the EIT-6-GFP protein was detected only in the nucleus. Similar results were obtained by Western blot analysis of fractionated cell extracts prepared from cells expressing a hemaglutinine epitope tagged EIT-6 protein (data not shown). We were unable to determine the localization of the endogenous EIT-6 protein, since the polyclonal antibodies we generated were not suitable for immunohistochemical analysis. However, based on these data EIT-6 is likely to be located and function in the nucleus.
Based on its homology to SM-20 we hypothesized that EIT-6 expression in¯uences cell proliferation and/ or survival. In order to test this, we transfected T47D ER+breast cancer cells with control (pCEP4) or pCEP4-EIT6 (encoding a C-terminal hemaglutinin epitope tagged EIT-6 protein) constructs. Stable transfectants were selected by culturing the cells in the presence of hygromycin for 2 weeks after which colonies were visualized by crystal violet staining. The expression of EIT-6 was con®rmed by immunoblot analysis of cell extracts prepared from pools of stable clones using anti-HA antibody (data not shown). In three independent experiments performed in duplicatē asks, expression of EIT-6 led to a signi®cant (3 ± 4-fold) increase in colony numbers (representative examples Figure 3d , summary of colony counts in Figure 3e ). Similar results were obtained in MDA-MB-435S ER negative breast cancer cells (data not shown). These data indicate that EIT-6 overexpression enhances colony growth in human breast cancer cells.
To test if expression of EIT-6 can confer estrogen independent growth, we transfected the ER+and estrogen dependent T47D breast cancer cells with control pCEP4 or pCEP4-EIT6 constructs. Stable transfectants were selected by culturing the cells in the absence of hormones in phenol red free medium supplemented with 5% charcoal/dextran treated fetal bovine serum and hygromycin. Half of the¯asks were cultured in the presence of 10 nM estrogen. Colonies were visualized by crystal violet staining after 2 weeks of selection. Very few colonies were observed in the absence of estrogen in control pCEP4 transfected cells con®rming the requirement of estrogen for T47D cell growth (Figure 3e ). In contrast, a signi®cant number of colonies was observed in EIT-6 transfected cells in the absence of estrogen indicating that EIT-6 expression relieves estrogen dependency (Figure 3e ). Addition of estrogen increased colony numbers in both control pCEP4 and EIT-6 transfected cells, therefore, EIT-6 expression may not be sucient to completely alleviate estrogen dependence (Figure 3e ). Due to the lack of suitable antibodies we were unable to determine the relative levels of ectopic and endogenous EIT-6 proteins in these clones. Therefore, the possibility that increased colony numbers were due to exogenous EIT-6 protein levels signi®cantly exceeding endogenous estrogen induced EIT-6 protein levels cannot be excluded.
In summary, based on SAGE analysis of estrogen and tamoxifen treated breast cancer cells, we identi®ed several novel putative targets of the estrogen signaling pathway. One of these genes, EIT-6, may be involved in transmitting growth promoting signals initiated by estrogen in human breast cancer cells. EIT-6 has no known functional domains and EIT-6 homologues are not well characterized, therefore, we can only speculate on how EIT-6 may regulate estrogen dependent and independent cell growth. Since EIT-6 is a nuclear protein one attractive hypothesis is that EIT-6 may in¯uence the transcription of genes involved in the regulation of cell proliferation or survival. However, further studies are required to determine if EIT-6 or any of the other genes are critical downstream components of the estrogen signaling pathway.
Note added in proof During the review of this manuscript two independent studies (Epstein et al., Cell, 107, 43 ± 54 and Bruick et al., Science, 294, 1337 ± 1340 ) identi®ed EIT-6 as a dioxygenase that may regulate HIF (hypoxia inducible factor) by hydroxylation.
